Ⓐ
PeptiBrief
Endogenous neuropeptide

Urocortin-II

A CRF2-selective endogenous peptide investigated for cardiovascular, heart-failure and skeletal-muscle effects.

Evidence confidence

Human
3/5
Multiple human studies
3 citations
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
2/5
Partially characterised safety
1 citation

Claimed uses

Mechanisms

Safety notes

Potential risks include hypotension, tachycardia, headache and unpredictable cardiovascular responses.

Regulation
  • Not approved as a general heart-failure, muscle-growth or wellness treatment.

References

  1. Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure · 2016
  2. Vascular effects of urocortins 2 and 3 in healthy volunteers · 2013
  3. Urocortin 2 infusion in human heart failure · 2007
Last reviewed
12 July 2026
Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.